Navigation Links
RXi Pharmaceuticals Announces Positive Data in Second Phase 1 Multi-Dose Study
Date:7/12/2013

owered the actual protein content for CTGF also in a dose-dependent manner. With this exciting outcome, we are ready to embark on Phase 2 development in patients with hypertrophic scars and keloids."

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals Corporation (OTC: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, self-delivering RNAi platform. Therapeutics that use RNA interference, or "RNAi," have great  promise because of their ability to down-regulate, the expression of a specific gene that may be over-expressed in a disease condition. Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, a member of the RXi Scientific Advisory Board, RXi's first RNAi product candidate, RXI‑109, targets connective tissue growth factor (CTGF) to reduce dermal scarring (fibrosis), entered into human clinical trials in June 2012.  For more information, please visit www.rxipharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future expectations, planned and future development of RXi Pharmaceuticals Corporation's products and technologies. Forward-looking statements about expectations and development plans of RXi's products involve significant risks, and uncertainties: risks that RXi may not be able to successfully develop its candidates, or that development of RNAi-based therapeutics may be delayed or not proceed as planned, or that we may not develop any RNAi-based product; risks that the development process for our product candidates may be delayed, risks related to development and commercialization of products by our competitors, risks related to our ability to
'/>"/>

SOURCE RXi Pharmaceuticals Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. UCBs Kremers Urban Pharmaceuticals Inc. receives FDA approval for extended release methylphenidate hydrochloride
2. Tris Pharmas Generic Pharmaceuticals Business Launches Dextroamphetamine Sulfate Oral Solution
3. Breckenridge Announces Dismissal of Various Lawsuits Against Macoven Pharmaceuticals in Return for Macovens Discontinuance of Certain Products
4. Kinex Pharmaceuticals Will Take the Lead in the Orascovery Program Development in China
5. Actinium Pharmaceuticals Clinical Results Featured at a United Nations Forum
6. Vanda Pharmaceuticals to Participate in Upcoming Investor Conferences
7. Vanda Pharmaceuticals, Inc. Sued by Investor
8. Avanir Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
9. Valeant Pharmaceuticals Announces Closing of Public Offering of Common Shares
10. Anthera Pharmaceuticals Announces Receipt of Nasdaq Notice
11. Oramed Pharmaceuticals to Present Findings on Oral Insulin to the American Diabetes Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... 2, 2015 Numotion,s Board of Directors and ... Tamas Feitel has joined the Company as ... a highly successful 18 year career at GE serving ... profitability, and productivity to result in significant industry leading ... Chief Financial Officer for GE Healthcare Global Services, a ...
(Date:7/2/2015)... , July 2, 2015 The ... & Heterofermentative), Species (Lactobacillus, Pediococcus & Enterococcus), Enzymes (Fibre-digesting ... Forecast to 2020", Silage Inoculants & Enzymes Market is ... CAGR of 4.0% from 2015 to 2020. ... igures spread through 194 P ages ...
(Date:7/2/2015)... 2015 BGI anunció hoy que su laboratorio ... en Hong Kong ha sido ... de BGI en Hong Kong ... que recibe la certificación CAP en China ... de laboratorio clínico. Junto con el exitoso proceso de ...
Breaking Medicine Technology:Numotion Names Tamas Feitel Chief Financial Officer 2Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 2Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 3Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 4BGI recibe la acreditación del College of American Pathologists (CAP) 2
... 18, 2011 PharmaNet Development Group, Inc., an ... clinical development services to pharmaceutical, biotechnology, generic drug ... has appointed George Scott, PhD, as Vice President, ... provide leadership for PharmaNet,s GLP-compliant bioanalytical laboratories in ...
... 18, 2011 Luminex Corporation (NASDAQ: LMNX ... the second quarter of 2011 on Monday, August 8, ... for release after the close of trading. ... hold a conference call to discuss the operating highlights ...
Cached Medicine Technology:PharmaNet Names Dr. George Scott Vice President of Bioanalytical Services 2Luminex Corporation Second Quarter Earnings Release Scheduled for August 8, 2011 2Luminex Corporation Second Quarter Earnings Release Scheduled for August 8, 2011 3
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... ... the newest shades of the SIGVARIS PERFORMANCE SOCKS. Since the socks were first ... and athletic trainers. Their significant popularity has inspired four new, fun shades including: ...
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... ActiveBunch.com recently ... passion for social fitness. Built to function as a lifestyle community, Active Bunch allows ... the opportunity to network, meet, and participate in discussions or group events. , ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... company , announced today that it has reached an agreement to acquire ... CleanItSupply.com the largest distributor of Rubbermaid Commercial Products on the web today. ...
(Date:7/2/2015)... ... July 02, 2015 , ... Octo Consulting Group, (Octo), a ... government, has announced they are among nine contractors awarded the U.S. Securities and ... contract not to exceed $250 million. , To achieve the goals of ...
(Date:7/2/2015)... OR (PRWEB) , ... July 02, 2015 , ... Hand ... During the current summer flu season, according to fresh water advocate and radio host ... on the hands. Kleyne cautions that for maximum effectiveness, hand sanitizers must be applied ...
Breaking Medicine News(10 mins):Health News:SIGVARIS is Sporting Four Brand New Colors in the Popular PERFORMANCE SOCK Product Line 2Health News:ActiveBunch.com Launches as a Social Community for People with Active Lifestyles 2Health News:CleanItSupply.com Acquires eRubbermaid.com 2Health News:Octo Consulting Group Awarded IDIQ Contract for SEC Business Management Support 2Health News:Summer flu season hand sanitizers are most effective when correctly applied reports fresh water advocate Sharon Kleyne 2Health News:Summer flu season hand sanitizers are most effective when correctly applied reports fresh water advocate Sharon Kleyne 3
... Inc. (CTI) (Nasdaq and MTA: CTIC) today announced that Richard Van der Jagt, M.D. of ... the 2009 Pan Pacific Lymphoma Conference on Monday, June 22, 2009. The conference will be ... Hawaii. , , , ... 2009 Pan Pacific Lymphoma Conference, ...
... , , , President Obama Calls For Health ... 15 The American Medical Association warmly welcomed U.S. ... Like the president, the AMA is committed to health reform this ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20081209/AMALOGO ) , ...
... MBA, FACPE, Ameritox,s Senior Vice President and Chief Medical Officer, ... for the American College of Physician Executives (ACPE), a national ... , Dr. Leider became an ACPE member 20 years ... College for 13 years teaching courses on improving the quality ...
... 16, 2009 at 9:00 a.m. Eastern Time , , ... ALXA ) announced today that it has exercised ... Allegro. The purchase of Symphony Allegro, which is subject ... 2009. , , Alexza and Symphony Capital Partners, LP ...
... June 15 Citing evidence that even a very low level ... the Council of State and Territorial Epidemiologists (CSTE) is recommending a ... adults. In a vote at the CSTE annual conference in Buffalo, ... 10 ug/dl or more in adults as "elevated" -- the same ...
... 15, 2009 (BRONX, NY) In a study ... researchers from Albert Einstein College of Medicine of Yeshiva ... HIV-positive individuals are most likely to develop deadly fungal ... of meningitis affects more than 900,000 HIV-infected people globallymost ...
Cached Medicine News:Health News:President Obama Receives Warm Welcome from AMA Physicians 2Health News:Ameritox(R) CMO Elected Chairman of the American College of Physician Executives Board 2Health News:Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002 2Health News:Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002 3Health News:Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002 4Health News:Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002 5Health News:Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002 6Health News:CSTE Leads Effort to Improve Blood Lead Reporting 2Health News:CSTE Leads Effort to Improve Blood Lead Reporting 3Health News:Predicting fatal fungal infections 2
The Surgiflex WAVE is a comfortable, easy to use, versatile, and interchangeable suction-irrigation device....
... Clinicians are demanding smaller, higher performing ... clinical and operational challenges. The new ... powerful architecture for superb High Definition ... and ease-of-use; and a versatile suite ...
The Cardiff Acuity Test is designed specifically for,acuity measurement in children aged 1 to 3 years. The,test is also helpful with other age groups with,intellectual impairment, dementia, hea...
... InfinixTM CF-i/SP brings revolutionary flexibility to ... enables operators to move the C-arm ... to obtain the optimal angle for ... features an 8-inch cardiac flat panel ...
Medicine Products: